In spite of enhancing the complete response (CR) rate with more cycles of neoadjuvant chemotherapy (NACT) only an early complete response (ECR) correlates with a better disease free survival (DFS) for larynx preservation (LP)
R. Giglio, Pablo Menéndez(Parque Tecnológico de la Salud), Ana Alvarez(Hospital Clínico San Carlos), Berta Roth, Luigi Califano(Federico II University Hospital), E. Mickiewicz(University of Chicago), R Pradier(Instituto de Oncología de Rosario), Maria Bonomi(Instituto de Oncología de Rosario), Pedro Saco(Instituto de Oncología de Rosario), V. Cuartero
Cited by 0
Related Papers
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
|Journal of Clinical Oncology|2000|318
The KMT2A recombinome of acute leukemias in 2023
|Leukemia|2023|214